Gilde Healthcare leads $24 million financing round of respiratory care provider Vapotherm - Gilde Healthcare

Gilde Healthcare leads $24 million financing round of respiratory care provider Vapotherm

April 7, 2014

EXETER, New Hampshire – Vapotherm, Inc. announced a $24MM financing round led by Gilde Healthcare. Adage Capital Management joined as new co-investor. The round was completed by existing investors Morgenthaler Ventures, Kaiser Permanente, 3×5 Special Opportunity Fund, Integral Capital Partners, QuestMark Partners and Cross Creek Capital.

Geoff Pardo, Partner of Gilde Healthcare joins as new member of the Board of Directors:

“Vapotherm’s unique respiratory solution has proven to generate superior patient outcomes and lower the cost of care for providers. We look forward to grow the company internationally and improve healthcare for patients world-wide.”

Vapotherm develops, manufactures and markets advanced respiratory care devices. The company sells innovative, comfortable, noninvasive technologies for respiratory support of patients with chronic or acute breathing disorders. Over 600,000 patients have been treated with Vapotherm’s proprietary high flow therapy. For more information, visit www.vtherm.com.

 

About Gilde Healthcare (www.gildehealthcare.com)

Gilde Healthcare (Utrecht, The Netherlands and Cambridge, Massachusetts) is a transatlantic growth capital investor focused on private healthcare companies. It has over €450 million ($600 million) under management and is actively looking to lead new investments in therapeutics, diagnostics, medical devices and healthcare services. For a list of Gilde’s portfolio companies please visit our new website at www.gildehealthcare.com.

Gilde Healthcare company CatalYm announces leadership changes to accelerate visugromab late-stage clinical development

Gilde Healthcare company CatalYm, a world-leader in neutralizing GDF-15 in cancer and cachexia, today announced changes to its executive leadership team to support its next stage of growth. The appointments of Clinton Musil as Chief...
September 15, 2025

Gilde Healthcare company Tagworks Pharmaceuticals Announces Initiation of Third Dose Level in Ongoing Phase 1 Clinical Trial of TGW101 for the Treatment of Solid Tumors

TGW101 is a next-generation, first-in-class ADC targeting TAG-72 with an MMAE payload, developed based on Tagworks proprietary Click-to-Release linker chemistry; TGW101 is the first bioorthogonal, in vivo click chemistry-activated ADC, which enables superior control of tumor...
September 10, 2025

Gilde Healthcare appoints Dr. Christian Stark as Group CEO of its globally operating medical technology group

The medical technology group, which includes two manufacturers of surgical instruments in the Tuttlingen region, Koscher & Würtz and Christian Diener, has appointed Dr. Christian Stark as Chief Executive Officer (CEO) with effect from September...
September 3, 2025